Lorna Hopcroft
Oncology R&D
Cambridge, ENG, United Kingdom
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Targeting the chromatin modifying enzyme, KDM5C, enhances AKT inhibition response in ER+ breast cancer.
Journal: Molecular cancer therapeutics
Published: August 22, 2025
The interplay between FOXO3 and FOXM1 influences sensitivity to AKT inhibition in PIK3CA and PIK3CA/PTEN altered estrogen receptor positive breast cancer.
Journal: NPJ breast cancer
Published: September 17, 2024
Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC.
Journal: Communications biology
Published: January 17, 2024
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer.
Journal: British journal of cancer
Published: September 25, 2023
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Journal: NPJ breast cancer
Published: September 19, 2023
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Journal: NPJ breast cancer
Published: August 18, 2023
Chemical Biology Approaches Confirm MCT4 as the Therapeutic Target of a Cellular Optimized Hit.
Journal: ACS chemical biology
Published: January 05, 2023
Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology.
Journal: Journal of medicinal chemistry
Published: December 16, 2022
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Journal: NPJ breast cancer
Published: October 19, 2022
Showing 1-10 of 10
Last Updated: 09/26/2026